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Abstract The clinical diagnosis of sporadic Creutzfeldt–
Jakob disease (sCJD) is difficult, and reliable markers are
highly desired. In this work we assess the value of several
cerebrospinal fluid (CSF) markers for sCJD diagnosis.
Within the framework of the Portuguese Epidemiological
Surveillance Program for Human Prion Diseases, CSF
samples from 71 patients with clinically suspected sCJD,
30 definite sCJD and 41 non-CJD patients, were analysed
for the presence of 14-3-3 protein. CSF levels of tau (t-tau),
and phosphorylated tau (p-tau181), S-100b and b amyloid
(Ab42) proteins were determined. The influence of clinical
and genetic characteristics on CSF markers sensitivity was
also evaluated. Protein 14-3-3 was detected in 29/30 sCJD
patients and 9/41 non-CJD patients. Extremely elevated
t-tau and S-100b protein levels were found in sCJD
patients, while p-tau181 levels were only slightly elevated
and Ab42 showed no differences compared to controls.
14-3-3 was the most sensitive parameter (97%), but its
specificity was low (78%); sensitivity/specificity for other
proteins were: S-100b—93/93%, t-tau—93/95%, with
maximum accuracy being obtained by a combination of
tests (14-3-3 combined with either t-tau or S-100b, or
combining S-100b with t-tau/Ab42 or p-tau/t-tau ratios).
The sensitivity of 14-3-3, as well as of p-tau181/t-tau ratio,
was decreased in younger patients with long disease
duration, with the PrP-2 isotype and MV genotype. Both
14-3-3, t-tau and S-100b are sensitive markers for sCJD,
but 14-3-3 specificity seems to be lower in this special
clinical setting of rapidly progressing dementias. We pro-
pose that in cases with a 14-3-3 weak positive result, or in
young patients with long disease duration, a second CSF
marker would be valuable for the diagnosis of sCJD.
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Introduction
Sporadic Creutzfeldt–Jakob disease (sCJD) is the most
common human prion disease. It causes a rapidly pro-
gressive neurodegeneration, ultimately leading to the
patient’s death within months to few years [27]. To date, a
definite diagnosis can only be made by neuropathological
examination of brain tissue with immunochemical
demonstration of the pathogenic isoform of the prion
protein (PrPSc) [4]. Clinically, the diagnosis of possible
sCJD is made based on neurological findings of rapidly
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progressive dementia (less than 2 years duration) together
with at least two of the following symptoms: myoclonus,
ataxia, pyramidal or extrapyramidal signs, akinetic mutism,
visual and psychiatric disturbances [26]. The heterogeneity
of the symptoms, especially early in the course of the
disease, may resemble other neurodegenerative disorders,
reinforcing the need for reliable intra vitam diagnostic
markers. Therefore, the probable diagnosis of sCJD is
based, not only on the clinical features and course of the
disease, but also on electroencephalography (EEG), mag-
netic resonance imaging (MRI) and cerebrospinal fluid
(CSF) findings [41]. EEG records are considered typical
when they fulfil validated criteria: sustained periodic sharp
wave complexes (PSWC) lasting 100–600 ms, with a
variability of \500 ms, demonstrating a bi- or tri-phasic
morphology and seen in generalized or lateralized distri-
bution [34]. Although, at present, cerebral MRI is not part
of the diagnostic criteria for sCJD, high signal in the
putamen and caudate nucleus when using long-repetition
time pulse sequences are considered characteristic [8].
In recent years, CSF analysis has become increasingly
important in the diagnosis of sCJD. Immunodetection of
protein 14-3-3 in CSF was originally demonstrated to have
a high sensitivity and specificity for sCJD [19, 42] and has,
therefore, been included by the World Health Organization
(WHO) in the diagnostic criteria for probable disease [41].
However, this view has been challenged by findings of
poor specificity [6, 7] and low sensitivity in autopsy-proven
sCJD cases [11]. One of the major limitations of this assay
is that the 14-3-3 immunoblot is usually analysed in a
qualitative manner, by visual inspection, leading to a sub-
jective interpretation of borderline results. Moreover, its
sensitivity is believed to be strongly influenced by disease
duration [9, 30, 39], and a number of other conditions that
lead to neuronal injury are known to give false positive
results. These include central nervous system infections,
cerebrovascular diseases, encephalopathies, brain tumours,
inflammatory conditions and other types of dementia.
In order to overcome some of these limitations, various
other brain-derived proteins have been studied in the CSF,
such as tau, phosphorylated tau, full length b-amyloid
(Ab42), S-100b and neuron-specific enolase (NSE) [36].
Following the principle that CSF proteins reflect changes in
pathological brain conditions, elevated levels of these
proteins are used as surrogate markers for neuronal damage
(14-3-3, tau, NSE) or astrocytic gliosis (S-100b). CSF total
tau (t-tau) reaches extremely high levels in sCJD, probably
reflecting the extent of the neurodegenerative process, and
has been reported to be clinically useful, with sensitivity
and specificity for sCJD similar to the 14-3-3 test [17, 22,
38, 39]. Unlike what happens in Alzheimer’s disease (AD),
hyperphosphorylation of tau and formation of neurofibril-
lary tangles (NFTs) do not occur in sCJD. As so the ratio
between phosphorylated tau (p-tau) and t-tau levels (p-tau/
t-tau) was shown to improve discrimination between AD
and sCJD, with lower levels in favour of the latter [5, 28,
32]. Reduced Ab42 CSF levels have also been reported in
sCJD patients, as in AD, but mostly overlapping [17, 38,
39]. NSE and S-100b are elevated in sCJD patients, but do
not seem to attain sufficient sensitivity and specificity for
differential diagnosis [21, 30, 43].
Most studies compared sCJD patients with either a
group of patients with a defined neurological condition
(mainly AD or fronto-temporal dementia) or with a control
group of individuals without dementia. In a clinical setting,
putative CSF markers would be most useful in identifying
sCJD cases in a cohort of mixed pathologies with a similar
presentation of rapidly progressive dementia and therefore
suspected to have sCJD. A few studies have addressed this
problem [2, 12, 39] with some limitations, either enrolling
a very limited number of patients, or assessing only two or
three different CSF markers.
In this study, conducted in the framework of the Portu-
guese Epidemiological Surveillance Program for Human
Prion Diseases, we evaluated the utility of several CSF pro-
tein markers (14-3-3 protein, t-tau, p-tau, Ab42 and S-100b)
in a population of patients with suspected sCJD. We also
analysed the influence of patients clinical and genetic char-
acteristics on the sensitivity/specificity of the CSF markers.
Methods
Sample characterization
Samples from patients with a clinical suspicion of CJD were
collected as part of their routine clinical diagnosis investiga-
tion and sent to our laboratory for the detection of 14-3-3
protein in CSF. Herein we report the results form the patients
for which a confirmatory diagnosis was available: 30 neuro-
pathologically confirmed sporadic CJD (sCJD), and 41
patients proved to have an alternative diagnosis (non-CJD).
The diagnosis of definite sCJD was made according to
standard, international agreed criteria [41], including post-
mortem neuropathological confirmation (29/30) or brain
biopsy. In the non-CJD group the appropriate diagnosis
criteria were used. This group included patients with the
following: Alzheimer’s disease (6), fronto-temporal
dementia (5), Lewy body dementia (6), vascular dementia
(5), reversible encephalopathy (5), acute psychosis (4),
Parkinson’s disease and other movement disorders (5),
neoplastic syndromes (4) and Whipple’s disease (1). These
diagnoses were established by histology or according to
clinical evolution. The study was performed in accordance
with the ethical standards laid down in the 1964 Declara-
tion of Helsinki.
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CSF proteins evaluation: 14-3-3, Ab42, t-tau, p-tau
and S-100b
CSF samples, collected in sterile polypropylene tubes, were
centrifuged at 2,500 rpm for 5 min, aliquoted and stored at
-80C until analysis. Immunodetection of protein 14-3-3 in
CSF was done as described previously [42], with minor
modifications. Briefly, CSF proteins were separated by
sodium dodecyl sulphate-polyacrylamide gel electrophore-
sis and detection was carried out by incubation with mouse
anti-14-3-3 beta monoclonal antibody (sc-1657, Santa Cruz
Biotechnology, USA) followed by horseradish peroxidase-
conjugated anti-mouse immunoglobulin (DakoCytomation,
Denmark). Membranes were developed by enhanced
chemiluminescence (SuperSignal, West Pico, PIERCE,
USA). A positive and a weak positive control (CSF from
patients with histopathologically confirmed sporadic CJD
with a strong or a weak protein 14-3-3 signal, respectively),
a negative control (CSF from a patient without histological
evidence of CJD and showing no protein 14-3-3 signal) and
molecular weight markers were included in the run. All
samples were tested twice and the result evaluated by three
independent observers. In cases of contradictory results or
when an agreement between the observers could not be
reached, a third test was made to establish a final result.
CSF Ab42, t-tau and p-tau-181 were measured by
commercially available sandwich ELISA kits (Innotest,
Innogenetics, Ghent, Belgium), according to the manu-
facturer instructions, as previously reported [12, 17] CSF
S-100b was measured by a commercially ELISA kit
(Sangtec 100 ELISA, DiaSorin, Stillwater, MN, USA),
according to the manufacturer instructions. All assays were
performed sequentially in a clinical routine setting.
PrP-isotypes determination
In 16 of the 30 definite sCJD cases, autopsy or biopsy
tissue was sent to the laboratory for PrP western blot
isotyping. For this purpose, brain tissue homogenates (10%
w/v) from cerebellum, frontal, occipital and temporal
cortex (when available), were prepared from frozen sam-
ples and digested with proteinase K (Roche Diagnostics
GmbH, Mannheim, Germany). Samples were then ana-
lysed by western blotting as previously described [16].
Molecular weight markers and proteinase K-digested brain
extracts of histopathologically confirmed sCJD cases were
included in each run. Detection was made using first anti-
PrP monoclonal antibody and then horseradish peroxidase-
conjugated anti-mouse immunoglobulin and streptavidin
peroxidase (all from DakoCytomation, Denmark). The
membranes were developed using chemiluminescent sub-
strate (SuperSignal, West Pico, Pierce Biotechnology,
Rockford, USA).
ApoE and PRNP genotyping
A subset of patients was genotyped for ApoE (25 sCJD and
29 non-CJD) and PRNP genes (28 sCJD). Blood samples
were collected into EDTA tubes and DNA was isolated
from whole blood using a commercial kit (Roche Diag-
nostics GmbH, Manheim, Germany), as described by the
manufacturer.
ApoE genotype was determined by polymerase chain
reaction-restriction fragment length polymorphisms (PCR-
RFLP) assay, as previously described [10].
The open reading frame (ORF) of PRNP gene was
amplified by PCR using the following primers: forward—
Pr-85/-62 50-GCT ATG CAC TCA TTC ATT ATG CAG-
30 and reverse—Pr ? 79/? 57 50-CTA AAA GGG CTG
CAG GTG GAT AC-30. DNA sequencing of the amplified
product was done using the ABI PRISMTM Dye Terminator
Cycle Sequencing System (Perkin-Elmer, Norwalk, CA).
The obtained sequence was compared with the PRNP
sequence deposited in GeneBank M13899 (http://www.
ncbi.nlm.nih.gov/Genbank).
Statistical analysis
Statistical analysis was performed using the program SPSS
13.0. The Kolmogorov–Smirnov test showed that the
results obtained with t-tau, p-tau and S-100b did not have a
normal distribution, therefore the Mann–Whitney U test
was used for comparing these variables between diagnostic
groups and within groups. For continuous variables
showing a normal distribution (age, duration of disease and
Ab42), the Student’s t test was used. For comparison of
quantitative parameters between different ApoE genotypes,
either one-ANOVA followed by the Bonferroni post-test or
the non-parametric Kruskal–Wallis test were used. v2 test
was used to assess differences between categorical vari-
ables and to test differences in sensitivity between CSF
markers. Receiver operating characteristics (ROC) curve
analysis was used to define the sensitivity, specificity and
optimal cut off values of the different markers. Spearman’s
test was used for correlation between parameters. Data in
the text are presented as mean ± standard error of means
(SEM).
Results
Clinical and molecular characterization of the patients
The principal features of all patients for whom a definite
diagnosis was available are summarized in Table 1. There
were no differences regarding gender or age between the
sCJD and the non-CJD group, but disease duration was
1542 J Neurol (2009) 256:1540–1550
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significantly shorter in the sCJD group. We also assessed
the prevalence of symptoms in definite sCJD and non-CJD
patients at the time of lumbar puncture (Table 2).
Dementia was present in all patients, and at least one other
symptom was present in all but four patients (non-CJD
group). Myoclonus, ataxia, akinetic mutism or severe
psychomotor slowing and inhibition were significantly
more common in the sCJD group. Extrapyramidal or
pyramidal signs and psychiatric problems were equally
found in both groups. Visual problems were the least
common of symptoms, showing also no difference between
sCJD and non-CJD patients. Results regarding the principal
diagnostic tests performed in sCJD suspected cases (EEG,
cerebral MRI and CSF 14-3-3 immunoassay) are also
shown in Table 1. The number of positive EEGs in the
sCJD group was statistically higher than the number of
typical sCJD-EEG results in the non-CJD group, resulting
in a sensitivity of 65% and a specificity of 86%. Cerebral
MRI showed a rather low sensitivity (40%), but a very high
specificity (95%), with only one out of 19 non-CJD patients
(a patient with Whipple’s disease) presenting with
increased signal intensity in the caudate nucleus head.
Concerning molecular characteristics, PRNP codon 129
genotyping was available in 28 sCJD patients and PrP
isotyping was performed in 16 patients (see Table 1). PrP
type-1 was the most common (81%) and the frequency of
the various PRNP genotypes was as follows: 64% MM,
21% MV, and only 14% VV. Combining these two fea-
tures, it was possible to determine the molecular subtypes
of 15 sCJD patients (not shown): 7 MM1, 4 MV1, 1 MV2,
1 VV1 and 2 VV2. The distribution of the different ApoE
genotypes was not statistically different between the
diagnostic groups, although there were differences
regarding the frequency of e4 alleles (P \ 0.05). Only
three out of 25 sCJD patients carried one e4 allele for
ApoE, whereas in the non-CJD group close to half of them
(13 out of 29) had at least one e4 allele. Within the sCJD
group, there was a trend for individuals with e2e3 genotype
to be older and with longer disease duration (P [ 0.05; not
shown).
CSF proteins profile
From the three diagnostic tests, CSF 14-3-3 immunoassay
was by far the most sensitive, with 29 out of 30 sCJD
patients presenting with a positive result (both positive and
weak positive signals considered). A weak 14-3-3 band
was also observed in three patients with encephalopathies,
two Lewy body dementia, one Alzheimer’s disease, one
fronto-temporal dementia, one vascular dementia and one
paraneoplastic syndrome. Overall, 14-3-3 test showed a
sensitivity of 97% and a specificity of 78%. Only one sCJD
patient had a negative 14-3-3 result. This patient is a young
woman (age 47), with an isolated dementia evolving over a
2-year period, with no investigational feature, except for
the MRI, suggestive of sCJD and molecular subtype MV2
(A´. Machado, personal communication). Final diagnosis
was made following brain biopsy.
Cerebrospinal fluid concentrations of Ab42, t-tau,
p-tau181, S-100b, and the t-tau/Ab42 and p-tau181/t-tau
ratio for both sCJD and non-CJD patients are shown in
Fig. 1. No significant difference in mean CSF Ab42 con-
centration was seen between sCJD and control groups
(454.3 ± 47.5 vs. 490.1 ± 39.6 pg/mL; P [ 0.05; Fig. 1a).
Unlikely, CSF t-tau (Fig. 1b) and S-100b levels (Fig. 1d)
Table 1 Clinical features and principal investigation findings of all
patients
sCJD
(n = 30)
Non-CJD
(n = 41)
Gender (M/F) 13/17 19/22
Age, years (min–max) 68.3 ± 1.7
(47–84)
63.6 ± 2.1
(16–84)
Duration disease, months
(min–max)
3.7 ± 0.8**
(1–21)
10.2 ± 2.4
(1–84)
ApoE genotype e2e3—5 e2e3—4
e2e4—0 e2e4—1
e3e3—17 e3e3—12
e3e4—3 e3e4—11
e4e4—0 e4e4—1
PRNP codon 129 genotype MM—18 –
MV—6
VV—4
PrP isotype Type 1—13 –
Type 2A—3
EEG—typical/total (%) 17/27 (65)*** 4/28 (14)
MRI—characteristic/total (%) 10/25 (40)** 1/19 (5)
14-3-3 in CSF (Pos/Wp/Neg) 26/3/1*** 0/9/32
Data are expressed as mean ± SEM
Pos Positive, Wp weak positive, Neg negative
** P \ 0.005 versus non-CJD; *** P \ 0.0001 versus non-CJD
Table 2 Prevalence of symptoms in sCJD and non-CJD patients
sCJD, %
(n = 30)
Non-CJD, %
(n = 41)
Myoclonus 77** 42
Ataxia 77*** 29
Extrapyramidal and/or pyramidal signs 60 54
Akinetic mutism 43* 17
Visual problems 23 12
Psychiatric problems 60 68
Data are expressed as percentage of total
* P \ 0.05 versus non-CJD; ** P \ 0.005 versus non-CJD;
*** P \ 0.0001 versus non-CJD
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were markedly increased in sCJD patients (t-tau: 12
186.9 ± 2 333.6 vs. 385.7 ± 67.7 pg/mL; P \ 0.0001;
S-100b: 7.80 ± 1.14 vs. 1.39 ± 0.17 pg/mL; P \ 0.0001).
However, this huge increase in t-tau CSF levels in sCJD
patients was not accompanied by a similar change in
p-tau181 levels, which were only slightly increased
(37.1 ± 4.0 vs. 25.7 ± 2.9 pg/mL; P \ 0.05; Fig. 1c).
These profiles of CSF t-tau and p-tau181 resulted in a strong
increase in the t-tau/Ab42 ratio (29.6 ± 4.0 vs. 1.3 ± 0.3;
P \ 0.0001; Fig. 1e) and a marked decrease in the p-tau181/
t-tau ratio in the sCJD group (0.67 ± 0.19 vs. 10.30 ± 1.03;
P \ 0.0001; Fig. 1f). In the sCJD group, but not in the non-
CJD group, positive correlations between t-tau, p-tau181 and
S-100b CSF levels were observed (Fig. 2).
Table 3 shows the sensitivity and specificity levels,
derived from ROC curve analysis, of the assessed protein
markers. Ab42 and p-tau181 were excluded from this
analysis, as their diagnostic accuracy between sCJD and
non-CJD was shown to be very low (AUC \ 0.700 for both
cases). For both t-tau and S-100b, we found an increased
specificity, although a slightly lower sensitivity as com-
pared with the 14-3-3 immunoblot. Discriminative power
between sCJD and non-CJD was highest for t-tau/Ab42
and p-tau181/t-tau ratios, correctly allocating 94% of the
cases (67 out of 71). S-100b and t-tau alone correctly
diagnosed 66 cases (93%), while 14-3-3 immunoassay,
although being the most sensitive test, presented the lowest
number of correctly allocated cases (86%; 61 out of 71).
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Combination of tests clearly resulted in improved accuracy.
Association of protein 14-3-3 with any of the other protein
markers improved specificity (from 78 to 95–98%), and
association with S-100b protein also resulted in an increase
of sensitivity from 97 to 100%. The combination of 14-3-3
protein with t-tau or p-tau/t-tau ratio failed to correctly
allocate two non-CJD patients (a 41-year-old male with an
encephalopathy and a 58-year-old female with vascular
dementia) and one sCJD patient (the 47-year-old female,
with a long disease duration, previously mentioned).
Combining 14-3-3 protein with S-100b failed only to
correctly diagnose a 51-year-old male, with a fronto-tem-
poral dementia evolving over a 18 months period. Com-
bination of S-100b with the other quantitative protein
markers also improved accuracy, with the association with
t-tau correctly allocating all non-CJD cases and only failing
to allocate one sCJD patient (a 69-year-old male, with a
2 months duration dementia). Associating S-100b with
either t-tau/Ab42 or p-tau181/t-tau ratios showed to be
particularly advantageous, resulting in a correct allocation
of 100% of the cases.
Influence of age and disease duration on protein
markers
Next we have analysed the influence of age and disease
duration at the time of sampling in the different protein
markers assessed. For that we divided the patients in two
groups, either according to age (\60 and C60 years) or
disease duration (\12 and C12 months). In sCJD patients,
a CSF 14-3-3 protein positive test was more frequently
associated with older patients and shorter disease duration
(Table 4). Regarding quantitative markers, patients age did
not influence the levels of CSF Ab42 or S-100b levels, but
appeared to influence the levels of t-tau and p-tau181, with
younger sCJD patients presenting with a trend for lower
t-tau (\60 years = 6,291 ± 2,169 pg/mL; C60 years =
13,366 ± 2,719 pg/mL; P [ 0.05) and higher p-tau181
levels (\60 years = 43.4 ± 7.8 pg/mL; C60 years =
Table 3 Sensitivity and specificity of the different protein markers
tested for sCJD patients
Marker (cut-off value) Sensitivity
(%)
Specificity
(%)
AUC
(95% CI)
14-3-3 Protein (all bands) 97 78 –
t-tau ([1,203 pg/mL) 90 95 0.989***
(0.974, 1.005)
S100b ([2.59 pg/ml) 93 93 0.943***
(0.879, 1.007)
t-tau/Ab42 ([5.83) 93 98 0.985***
(0.963, 1.006)
p-tau181/t-tau 9 100
(\1.66)
93 95 0.980***
(0.956, 1.005)
AUC area under the curve, determined by ROC analysis
*** P \ 0.0001
Table 4 Findings for the
protein markers tested
according to age, duration of
illness, PRNP codon 129
genotype, PrP type and
molecular subtype in sCJD
patients
Classical subtype: MM1 and
MV1; non-classical subtype:
MV2, VV1 and VV2
14-3-3 ?: all bands considered;
t-tau ?: [1203 pg/mL: S100b
?: [2.59 pg/mL
t-tau/Ab42 ?:[5.83; p-tau/t-tau
?: [1.66
* P \ 0.05 versus age
\60 years; dP \ 0.05 versus
duration C12 months;
#P \ 0.05 versus PRNP
genotype MM; nP \ 0.05 versus
PrP-type1
14-3-3
?/total (%)
t-tau
?/total (%)
S100b
?/total (%)
t-tau/Ab42
?/total (%)
p-tau/tau
?/total (%)
Age (years)
\60 4/5 (80) 4/5 (80) 5/5 (100) 4/5 (80) 3/5 (60)
C60 25/25 (100)* 23/25 (92) 23/25 (92) 24/25 (96) 25/25 (100)*
Duration (months)
\12 27/27 (100) 25/27 (93) 25/27 (93) 26/27 (96) 27/27 (100)
C12 2/3 (67)d 2/3 (67) 3/3 (100) 2/3 (67) 1/3 (33)d
PRNP
MM 18/18 (100) 17/18 (94) 16/18 (89) 18/18 (100) 18/18 (100)
MV 5/6 (83) 4/6 (67) 6/6 (100) 4/6 (67)# 4/6 (67)#
VV 4/4 (100) 4/4 (100) 4/4 (100) 4/4 (100) 4/4 (100)
PrP type
1 13/13 (100) 11/13 (85) 12/13 (92) 12/13 (92) 13/13 (100)
2A 2/3 (67)n 2/3 (67) 3/3 (100) 2/3 (67) 2/3 (67)n
Subtype
Classical 11/11 (100) 9/11 (82) 10/11 (91) 10/11 (91) 11/11 (100)
Non-classical 3/4 (75) 3/4 (75) 4/4 (100) 3/4 (75) 3/4 (75)
Subtype
MM1 7/7 (100) 6/7 (86) 6/7 (86) 7/7 (100) 7/7 (100)
MV1 ? MV2 4/5 (80) 3/5 (60) 5/5 (100) 3/5 (60) 4/5 (80)
VV1 ? VV2 3/3 (100) 3/3 (100) 3/3 (100) 3/3 (100) 3/3 (100)
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35.8 ± 4.5 pg/mL; P [ 0.05), resulting in a significantly
higher p-tau181/t-tau ratio (\60 years = 1.80 ± 1.04;
C60 years = 0.45 ± 0.07; P \ 0.05). Likewise, sCJD
patients with a longer duration of disease showed a trend
for higher p-tau181 levels (\12 months = 35.6 ± 4.2 pg/
mL; C12 months = 50.2 ± 13.8 pg/mL; P [ 0.05) and a
significantly higher p-tau181/t-tau ratio (\12 months =
0.46 ± 0.07; C12 months = 2.61 ± 1.68; P \ 0.05). In
accordance to these data, a p-tau181/t-tau ratio positive
result (i.e. \1.66) was less likely in younger patients and
longer disease duration (Table 4). Age and duration of
disease did not influence the levels of any of the protein
markers in the non-CJD group (data not-shown).
Influence of ApoE and PRNP genotypes on protein
markers
We looked for an influence of the ApoE genotype on the
levels of the protein markers assessed (data not shown).
This analysis is obviously limited by the very low
frequency of some of the genotypes, and the only signifi-
cant association found was between the presence of an e2
allele and higher CSF Ab42 levels in sCJD patients (with
e2 allele = 727.1 ± 117.1 pg/mL; without e2 allele =
382.7 ± 72.7 pg/mL; P \ 0.05).
In the sCJD group we also examined the influence of
PRNP codon 129 polymorphism, PrP-type and molecular
subtype on the sensitivity of the different markers. A
positive 14-3-3 result was found in all homozygotes (MM
and VV) or PrP-type1 patients, while the sensitivity of this
test was lower for the MV genotype and even lower for
PrP-type 2A subtype (Table 4). CSF levels of Ab42, t-tau
and S-100b seemed not to be influenced by any of these
characteristics (not shown). However, significantly lower
p-tau181 levels were associated with PrP-type1 patients
(PrP-type 1 = 32.9 ± 4.7 pg/mL; PrP-type 2A = 69.2 ±
8.2 pg/mL; P \ 0.05). Accordingly, a significant decrease
of p-tau181/t-tau ratio was also found in PrP-type1 patients
(PrP-type1 = 0.51 ± 0.08; PrP-type 2A = 2.65 ± 1.62;
P \ 0.05). In this subgroup of sCJD, all patients had a
positive p-tau181/t-tau ratio result, whereas only 67% of
PrP-type2 or heterozygotes (MV) tested positive for this
parameter (P \ 0.05; Table 4). The sensitivity of the t-tau/
Ab42 test was also lower in MV patients (P \ 0.05;
Table 4).
Due to the reduced number of patients for whom both
PRNP codon 129 polymorphism and PrP-type were avail-
able, we initially chose to consider only two different
molecular subtypes: classical (including MM1 and MV1
cases) and non-classical (including MV2 and all VV cases).
Both 14-3-3 and p-tau181/t-tau ratio seemed less sensitive
for the non-classical subtype, but the difference failed to
reach statistical significance (Table 4). Significantly lower
p-tau181 levels were associated with the classical molec-
ular subtype (classical = 32.9 ± 5.6 pg/mL; non-classi-
cal = 60.6 ± 10.4 pg/mL; P \ 0.05). Since cases of sCJD
show co-occurrence of type 1 and type 2 PrP in the brain
[35], and knowing that codon 129 genotype influences the
course of the disease, we have re-analysed the influence of
molecular subtype considering three different subtypes:
MM1; MV1 ? MV2A and VV1 ? VV2A. Although no
statistical significant differences were seen for any of the
protein markers tested (Table 4), there was a trend for
14-3-3, t-tau, t-tau/Ab42 ratio and p-tau181/t-tau ratio
sensitivity to be lower for the MV1 ? MV2A subgroup.
Discussion
In this work, performed under the scope of the Portuguese
Surveillance Network for Human Prion Diseases, we report
the results of a prospective study on biochemical markers
for sCJD. We assessed the value of 14-3-3 protein and
other protein markers in CSF, Ab42, t-tau, p-tau181 and
S-100b, as tools for the differential diagnosis of sCJD. Our
study group consisted of 30 definite sCJD patients, pre-
senting with a rapidly progressive dementia, associated in
most cases with myoclonus and ataxia. The control group
enrolled 41 age-matched patients, with a clinical suspicion
of sCJD, but in whom an alternative diagnosis was reached
(non-CJD). All non-CJD patients presented with dementia,
and in most cases another symptom, most often psychiatric
problems, could be found.
Regarding the molecular characteristics of the sCJD
group, the frequency of the various PRNP genotypes was
broadly in accordance with the frequency distributions
generally reported in the literature [9, 24]. Also as expected
[9, 24], most patients had a type-1 PrP isoform, and MM1
molecular subtype was the most frequent. There was
however, a fairly strong representation of the less frequent
MV1 subtype and one patient with the very rare VV1
subtype. The rare MM2 subtype was absent from our
population. ApoE genotyping was performed in a subset of
the population, showing no differences in the distribution
of the different genotypes between the two diagnostic
groups. However, a statistically lower frequency of the
ApoE-e4 allele was found in the sCJD group. This differ-
ence could, at least in part, be accounted by the fact that
our control group consisted of a population with a large
proportion of patients with other types of dementia,
including five patients with Alzheimer’s disease, for which
the ApoE-e4 allele is a well known risk factor. In fact, the
frequency of the ApoE-e4 allele for the sCJD group (12%)
is very similar to that we have found in the healthy
Portuguese population (10%) (unpublished data), and also
reported by others [20]. Contradictory results exist in the
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literature regarding the frequency and association of the
ApoE genotype with sCJD. While some authors consider
that there is no association between ApoE genotype and
sCJD [20, 31, 44], others postulate that ApoE-e4 allele is an
independent risk factor for sCJD [1, 37]. The discrepancy
between our results and those stated above, can be due to
the different control populations considered (other neuro-
logical condition with a clinical suspicion of sCJD vs.
healthy subjects), and also to regional differences in the
frequency of the ApoE genotypes [3, 23]. However, the
trend for the e2-allele to be associated with older sCJD
patients and with longer disease duration is in line with
evidence showing that this allele can delay the occurrence
of death in CJD patients [1].
From the commonly employed routine investigations for
the diagnosis of sCJD (EEG, CSF analysis and MRI), CSF
14-3-3 protein immunodetection was the most sensitive
(97% vs. 63% for EEG and 40% for MRI). This is in
agreement with recent data from an international collabo-
rative study [9], and with the majority of the literature
reporting the sensitivity of the 14-3-3 test [22, 30, 37, 39].
However, the specificity of the 14-3-3 assay, in our pop-
ulation, was clearly sub optimal (78%), lower than the EEG
(86%) and that reported in most previous studies [22, 30,
37, 39]. The poor specificity of the 14-3-3 assay, already
noted in some studies [6, 7], is probably related to the wide
range of pathologies included in our control population that
can lead to rapid and massive neuronal destruction.
Therefore, our results suggest that CSF protein 14-3-3
determination should not be used as a screening test for
sCJD. Another explanation for our low specificity can be
related to individual differences in evaluation of the pres-
ence of 14-3-3 and with the definition of positive bands.
There is no standard approach to this matter, with some
authors considering all bands [22], while others only con-
sidering strong bands as positive [30]. In fact, re-analysing
our data, considering only strong 14-3-3 bands as positive,
increases specificity to 100%, with sensitivity decreasing to
87%. To avoid person-to-person bias of visual inspection
and the difficult interpretation of weak bands, a densito-
metric analysis of the 14-3-3 immunoblots has been per-
formed [39]. The method resulted in an increase in
specificity but also in a decrease of the sensitivity com-
pared to the visual analysis. Other studies have compared
the western blot analysis with different enzyme linked
immunoassays (ELISAs), resulting in a similar specificity
but also a lower sensitivity [13, 18]. The difficulty of
standardization of the 14-3-3 immunoassay reinforces the
need for other protein markers.
From the different protein markers we have tested, and
as had been previously reported [17, 38, 39], Ab42 and
p-tau alone do not seem suitable to be used as diagnostic
markers for sCJD, as their levels largely overlap with those
found in the non-CJD group. The extremely high levels of
t-tau that we found in sCJD patients are in accordance with
other studies [5, 14, 22, 28, 32, 38, 39], with sensitivity
(87–94%) and specificity (90–100%) figures similar to
ours. In fact, t-tau has been suggested to be the most
sensitive marker in early stage sCJD [33]. The association
of t-tau and Ab42 (t-tau/Ab42 ratio) resulted in slight
improvement in both sensitivity (from 90% to 93%) and
specificity (form 95% to 98%). Furthermore, associating t-
tau with p-tau (p-tau/t-tau ratio) improved the sensitivity of
the t-tau test alone (from 90% to 93%), but not its speci-
ficity (95%). This is in line with previous studies, reporting
comparable sensitivity (78–100%) and specificity (93–
100%) [2, 5, 28, 32]. The increase in CSF S-100b levels
observed in sCJD patients has been previously reported,
but the absolute values are difficult to compare as different
methodologies have been employed [14, 30, 31]. Using a
commercial ELISA test for S-100b, we have reached a
sensitivity and specificity of 93%, both higher than those
reported using either an in-house ELISA or a different
commercial kit [21, 30, 43]. We tried to establish quanti-
tative correlations between the different biochemical
parameters and found positive correlations between the
levels of three proteins: t-tau, p-tau and S-100b in sCJD
patients, probably reflecting a relation between neuronal
damage and astrocytic gliosis.
Dividing sCJD patients according to age (\60 and
C60 years) and disease duration (\12 and C12 months),
we found that these features influenced the sensitivity of
the 14-3-3 immunoassay and of the p-tau/t-tau ratio, but
not of the t-tau or S-100b test. Contradictory results exist
regarding this issue. Although disease duration clearly
seems to affect 14-3-3 sensitivity, the influence of age is
not so widely accepted [9, 30, 39]. As for t-tau and S-100b,
earlier studies failed to find any influence of age and/or
disease duration on these protein markers sensitivity
[17, 39], but a more recent study, conducted in a large
population of CJD patients, succeeded in doing so [30].
Other factors known to influence the sensitivity of CSF
protein 14-3-3 testing are PRNP codon 129 polymorphism
and PrP-isotype. In our work, all PrP-type 1 and homozy-
gotes for PRNP 129 polymorphism had a positive 14-3-3,
whereas two out of three PrP-type 2A and five out of six
MV cases, had a positive signal. This difference failed to
reach statistical significance, probably due to the limited
number of MV and PrP-type 2A patients, but is in agree-
ment with the findings of large collaborative studies
[9, 30]. In relation to the other protein markers, t-tau and
S-100b have also reported higher sensitivity for MM or VV
than for MV patients, and also for PrP-type 1 patients [30].
There was a trend for such a difference for t-tau test in our
study, with 96% of homozygotes and 85% of PrP-type 1
patients testing positive, but only 67% of MV or PrP-type 2
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cases having a positive t-tau value. In relation to these
molecular characteristics, we could find statistical signifi-
cant differences in sensitivity for the t-tau/Ab42 (lower for
MV) and for p-tau/t-tau test (lower for MV and PrP-type
2A cases). In our hands, S-100b seemed largely indepen-
dent of all these molecular characteristics, showing a high
sensitivity for all subgroups of patients and was the only
marker that could positively identify the atypical sCJD case
that had a negative 14-3-3. Regarding the influence of the
molecular subtype on protein markers sensitivity, and
comparing the different approaches that we have used, we
can see that considering three different subtypes (MM1,
MV1 ? MV2A, VV1 ? VV2A) has similar results than
dividing the patients in relation only to PRNP codon 129
polymorphism. Therefore, it seems that PRNP polymor-
phism has a stronger influence than PrP-type on markers
sensitivity, which is in agreement with the co-occurrence of
type 1 and type 2 PrP in the brain of sCJD patients [35].
This seems to argue against the conventional classification
of molecular subtypes into classical and non-classical, and
might be of relevance to patients diagnosis, since PRNP
polymorphism is the only characteristic that can be deter-
mined during the patient life.
Overall, 14-3-3 and p-tau/t-tau ratio were the markers
most influenced by the patients characteristics, with a
sensitivity higher for older patients ([60), short disease
duration (\12 months), homozygotes for PRNP codon 129
and PrP-type 1. Despite the fact that the relatively small
number of patients might limit the conclusions taken from
this analysis, these are in general agreement with the
results from large population studies [9, 30]. This differ-
ence in the protein markers sensitivity between sCJD
subtypes might be accounted by the modulation of clinical
phenotype by molecular characteristics. A host genotype
effect has been reported, with codon 129 heterozygosity
increasing the duration of illness, [15] and prion strain
influencing disease onset [9]. In fact, in our study, there
was a trend for MV and PrP-type 2A patients to be younger
and with a longer disease course (data not shown).
Therefore, patients with an early disease onset and a less
rapidly progressive disease course would present with less
age-dependent neuronal vulnerability and less acute neu-
ronal damage [25], leading to a less pronounced release of
brain-derived proteins into the CSF. This is in agreement
with the fact that, in our hands, S-100b, a protein that
reflects astrocytic gliosis was the only marker independent
of patients molecular characteristics, while 14-3-3, t-tau
and p-tau, that reflect neuronal damage, were all influenced
by codon 129 genotype and PrP-type.
Comparing with a single marker, the combination of
tests (14-3-3 with either elevated levels of t-tau or S-100b,
or combining S-100b test with the ratios of two other
proteins—t-tau/Ab42 or p-tau/t-tau) clearly improved the
sensitivity and specificity to optimal levels. We, therefore,
propose that, besides from 14-3-3 protein, a second CSF
protein marker should be used in clinical practice for sCJD
diagnosis. This would be specially advised in cases where
14-3-3 gives a weak positive result, or in cases with an
atypical presentation, like younger patients with long dis-
ease duration and/or heterozygotes for the PRNP codon
129.
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